ALKRearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment

2014 ◽  
Vol 138 (11) ◽  
pp. 1449-1458 ◽  
Author(s):  
Greta Alì ◽  
Agnese Proietti ◽  
Serena Pelliccioni ◽  
Cristina Niccoli ◽  
Cristiana Lupi ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Small Cell ◽  
Large Series ◽  
Small Cell Lung ◽  
Lung Cancers

scholarly journals Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization

2018 ◽  
Vol 142 (8) ◽  
pp. 922-928 ◽  
Author(s):  
Peter P. Luk ◽  
Christina I. Selinger ◽  
Annabelle Mahar ◽  
Wendy A. Cooper
Keyword(s):  
Lung Cancer ◽  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Kinase Inhibitors ◽  
Screening Method ◽  
Genetic Alterations ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers

Context.— A small proportion of non–small cell lung cancers harbor rearrangements of ALK or ROS1 genes, and these tumors are sensitive to targeted tyrosine kinase inhibitors. It is crucial for pathologists to accurately identify tumors with these genetic alterations to enable patients to access optimal treatments and avoid unnecessary side effects of less effective agents. Although a number of different techniques can be used to identify ALK- and ROS1-rearranged lung cancers, immunohistochemistry and fluorescence in situ hybridization are the mainstays. Objective.— To review the role of immunohistochemistry in assessment of ALK and ROS1 rearrangements in lung cancer, focusing on practical issues in comparison with other modalities such as fluorescence in situ hybridization. Data Sources.— This manuscript reviews the current literature on ALK and ROS1 detection using immunohistochemistry and fluorescence in situ hybridization as well as current recommendations. Conclusions.— Although fluorescence in situ hybridization remains the gold standard for detecting ALK and ROS1 rearrangement in non–small cell lung cancer, immunohistochemistry plays an important role and can be an effective screening method for detection of these genetic alterations, or a diagnostic test in the setting of ALK.

Sign in / Sign up

Export Citation Format

Share Document